
CLAIMS

1. A combination of an SGLT2 inhibitor and an antihypertensive drug;
for use in the treatment of a disease
involving at least hypertension or diabetes mellitus
as a risk factor of cardiovascular events.

2. The combination according to claim 1, wherein the SGLT2 inhibitor is a 1-thio-D-glucitol compound represented by the below-indicated general formula (I), a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt:

[Formula 1]



(I)

[in formula (I),

R^A represents a hydrogen atom, a C_{1-6} alkyl group, $-OR^F$, or a halogen atom;

R^B represents a hydrogen atom, a hydroxy group, or $-OR^F$;

R^C and R^D, which may be the same or different, each represent a hydrogen atom, a halogen atom, a C_{1-8} alkyl group, or $-OR^F$;

R^E represents (i) a hydrogen atom, (ii) a halogen atom, (iii) a hydroxy group, (iv) a C_{1-8} alkyl group optionally substituted by a halogen atom, (v) $-OR^F$, or (vi) $-SR^F$, with R^F representing a C_{1-6} alkyl group optionally substituted by a halogen atom.]

3. The combination according to claim 2, wherein the 1-thio-D-glucitol compound is selected from the group consisting of:

(1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol;

(1S)-1,5-anhydro-1-[4-chloro-3-(4-methylbenzyl)phenyl]-1-thio-D-glucitol;

(1S)-1,5-anhydro-1-[4-chloro-3-(4-methylthiobenzyl)phenyl]-1-thio-D-glucitol; and

(1S)-1,5-anhydro-1-[4-chloro-3-(4-ethylbenzyl)phenyl]-1-thio-D-glucitol.

4. The combination according to claim 2 or 3, wherein the 1-thio-D-glucitol compound is (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol.

5. The combination according to any one of claims 1 to 4, wherein the antihypertensive drug is a suppressor of the renin-angiotensin-aldosterone system.

6. The combination according to claim 5, wherein the suppressor of the renin-angiotensin-aldosterone system is an ACE inhibitor or an angiotensin II receptor blocker.

7. The combination according to claim 6, wherein the ACE inhibitor is a compound selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt.

8. The combination according to claim 6, wherein the angiotensin II receptor blocker is a compound selected from the group consisting of losartan, candesartan, irbesartan, valsartan, telmisartan, and eprosartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt.

9. The combination according to claim 1, wherein the disease is hypertension.

10. The combination according to claim 1, wherein the disease is diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

11. The combination according to any one of claims 1 to 10, wherein the disease involves manifestations of both diabetes mellitus and hypertension.

12. The combination according to any one of claims 1-11, wherein the disease is diabetic nephropathy.

13. The combination according to any one of claims 1-11, wherein the disease further involves an observable lowered renal function.

14. A combination of an SGLT2 inhibitor and an antihypertensive drug;

for use in the treatment of a disease

involving at least hypertension or diabetes mellitus

as a risk factor of cardiovascular events, wherein the SGLT2 inhibitor and the antihypertensive drug are administered to a patient in need either simultaneously or

separately.

15. An SGLT2 inhibitor for use as a medicament in combination with an antihypertensive drug to thereby enhance the hypotensive action of the antihypertensive drug.

16. An SGLT2 inhibitor for use as a medicament in combination with an antihypertensive drug to thereby enhance the effect of the SGLT2 inhibitor in treating diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

17. An SGLT2 inhibitor for use as a medicament in combination with an antihypertensive drug to thereby enhance the effect of the SGLT2 inhibitor in treating diabetic nephropathy.

18. The use of an SGLT2 inhibitor and an antihypertensive drug in the manufacture of a medicament for the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events..

CLAIMS

1. A combination of (i) an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt for use in the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events.

2. The combination according to claim 1, wherein (i) and (ii) are either simultaneously or separately to be administered to a patient in need thereof.

3. The combination according to claim 1 or 2, wherein the disease is hypertension.

4. The combination according to claim 1 or 2, wherein the disease is diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

5. The combination according to any one of claims 1 to 4, wherein the disease involves manifestations of both diabetes mellitus and hypertension.

6. The combination according to any one of claims 1 to 5, wherein the disease is diabetic nephropathy.

7. The combination according to any one of claims 1 to 5, wherein the disease further involves an observable lowered renal function.

8. The combination according to claim 1 to enhance a hypotensive action of the antihypertensive drug.

9. The combination according to claim 1 to enhance the effect of the SGLT 2 inhibitor in the treatment of diabetes mellitus, a disease associated with diabetes mellitus, or a complication of diabetes mellitus.

10. The combination according to claim 1 to enhance the effect of the SGLT 2 inhibitor in the treatment of diabetic nephropathy.

11. The use of a combination of (i) an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, and (ii) an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt, in the manufacture of a medicament for the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events.

12. The use of an SGLT 2 inhibitor selected from the group consisting of (1S)-1,5-anhydro-1-[3-(4-ethoxybenzyl)-6-methoxy-4-methylphenyl]-1-thio-D-glucitol, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt in the manufacture of a first medicament and the use of an antihypertensive drug selected from the group consisting of lisinopril and valsartan, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or salt in the manufacture of a second medicament, both medicaments for the treatment of a disease involving at least hypertension or diabetes mellitus as a risk factor of cardiovascular events whereby each medicament is to be administered simultaneously or separately